GLP-RT

GLP-RT corresponds to retatrutide (LY3437943), a synthetic peptide engineered as a single-molecule triple agonist at the GLP-1, GIP, and glucagon (GCGR) receptors. It is built on a GIP-based backbone with fatty-acid acylation that confers albumin binding and an extended half-life, together with sequence modifications that balance activity across all three receptors. It is studied as a long-acting triple incretin/glucagon co-agonist reference compound.

The research literature attributes its activity to simultaneous agonism at three class-B G-protein-coupled receptors: GLP-1, GIP, and glucagon. In beta-cell and preclinical models, GLP-1- and GIP-receptor signaling are associated with glucose-dependent insulin secretion, while glucagon-receptor engagement is linked to increased hepatic lipid handling and cellular energy expenditure. The literature characterizes the combined profile as the product of balanced multi-receptor activation rather than any single pathway.

Contexts in which this compound appears in the in-vitro and preclinical research literature:

• Triple-receptor pharmacology assays at GLP-1, GIP, and glucagon receptors.
• Beta-cell culture: glucose-dependent insulinotropic signaling endpoints.
• Rodent models of diet-induced obesity examining energy-expenditure and hepatic-lipid markers.
• Comparative work against single- and dual-incretin agonists.
• Central appetite and energy-balance circuit studies.

Supplied lyophilized for laboratory reconstitution. Reconstitute with bacteriostatic water to the concentration your protocol requires (e.g. 2 mL into a 10 mg vial → 5 mg/mL). Add diluent slowly down the vial wall and swirl; do not shake. Aliquot after reconstitution to limit freeze–thaw exposure.

Store sealed lyophilized vials at −20 °C, protected from light. Reconstituted material should be refrigerated at 2–8 °C and protected from repeated freeze–thaw.

Independent and in-house certificates published for this compound. Each reports identity and HPLC purity for the tested lot.